Valiant Laboratories (VALIANTLAB) | Stock Overview & Key Data
Valiant Laboratories Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹214.95 on January 29, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Valiant Laboratories
VALIANTLAB
|
4.11B Small-cap | -6.80% | -2.50% | 42.11% | 14.63% | 8.43% | -24.91% | -54.51% | -54.51% | -54.51% | -54.51% | -54.51% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -3.03% | -1.92% | 2.17% | -1.01% | 3.92% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.25% | -0.65% | 4.12% | 1.88% | 3.66% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Sun Pharma Advanced
SPARC
|
46.75B Small-cap | -5.81% | 49.25% | 68.87% | 37.58% | 54.41% | 14.56% | 13.10% | -5.14% | -23.02% | 148.11% | -27.03% |
|
Innova Captab
INNOVACAP
|
41.43B Small-cap | 1.28% | 1.49% | 32.44% | 19.52% | 16.05% | -3.19% | 57.07% | 57.07% | 57.07% | 57.07% | 57.07% |
|
Gujarat Themis
GUJTHEM
|
35.41B Small-cap | -7.03% | 7.92% | 39.85% | 0.71% | -8.80% | 31.69% | 84.69% | 84.69% | 84.69% | 84.69% | 84.69% |
Ownership & Short Interest
Calculate Your Valiant Laboratories Investment Returns
Long-Term Investment Performance Analysis
Valiant Laboratories stock price in Oct 2023 was ₹170.25, A ₹1,000.00 lump sum investment in Valiant Laboratories made 2 years ago would be worth approximately ₹438.06 today, representing a negative return of -56.19%. This translates to an annualized return (CAGR) of -26.60%.
2 Years 8 Months Investment Scenario (Oct 2023 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is VALIANTLAB's 52-week high and low?
- In the last 52 weeks, Valiant Laboratories reached a high of ₹124.40 (on June 12, 2025) and a low of ₹49.51 (on March 4, 2026).
- What is the market cap and P/E ratio for VALIANTLAB?
- Curious about Valiant Laboratories's size and valuation? Its market capitalization stands at 4.11B. When it comes to valuation, the P/E ratio (trailing twelve months) is 266.77, and the forward P/E (looking ahead) is N/A.
- Does VALIANTLAB pay dividends? If so, what's the yield?
- As for dividends, Valiant Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Valiant Laboratories's main competitors or similar companies to consider before investing?
When looking at Valiant Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Sun Pharma Advanced
SPARC46.75B Healthcare Drug Manufacturers - Specialty & Generic 14.56% 13.10% Innova Captab
INNOVACAP41.43B Healthcare Drug Manufacturers - Specialty & Generic -3.19% 57.07% Gujarat Themis
GUJTHEM35.41B Healthcare Drug Manufacturers - Specialty & Generic 31.69% 84.69% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Valiant Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Valiant Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -0.94%, the Debt to Equity ratio from the most recent quarter is 16.94, and its Gross Profit Margin stands at 14.28%.
- What is the recent revenue and earnings growth for VALIANTLAB?
- Looking at Valiant Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 48.90%, and quarterly earnings saw a YoY growth of 48.90%.
- How much of VALIANTLAB stock is held by insiders and institutions?
- Wondering who owns Valiant Laboratories stock? Company insiders (like executives and directors) hold about 74.94% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.